Abstract:Background and objectives: Cognitive impairment is a frequent nonmotor symptom in patients with Parkinson disease (PD), and early cognitive decline is often attributed to dopaminergic system dysfunction. We aimed to explore spatiotemporal progression patterns of striatal dopamine availability and regional brain volume based on cognitive status among patients with PD. Methods: This retrospective, cross-sectional study included patients with newly diagnosed PD who were not taking medication for this condition who visited a university-affiliated hospital in Seoul between January 2018 and December 2020. Patients were classified as having normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or PD dementia (PDD) based on Seoul Neuropsychological Screening Battery-II, which includes 31 subsets covering activities of daily living and 5 cognitive domains. They all had brain imaging with MRI and PET with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane at baseline. Subsequently, standardized uptake value ratios (SUVRs) for regional dopamine availability and regional gray matter volumes were obtained using automated segmentation. These metrics were compared across cognitive status groups, and spatiotemporal progression patterns were analyzed using the Subtype and Stage Inference machine learning technique. Results: Among 168 patients (mean age, 73.3 ± 6.1 years; 81 [48.2%] women), 65 had PD-NC, 65 had PD-MCI, and 38 had PDD. Patients with PD-MCI exhibited lower SUVRs (3.61 ± 1.31, p < 0.001) in the caudate than patients with PD-NC (4.43 ± 1.21) but higher SUVRs than patients with PDD (2.39 ± 1.06). Patients with PD-NC had higher thalamic SUVRs (1.55 ± 0.16, p < 0.001) than patients with both PD-MCI (1.45 ± 0.16) and PDD (1.38 ± 0.19). Regional deep gray matter volumes of the caudate (p = 0.015), putamen (p = 0.012), globus pallidus (p < 0.001), thalamus (p < 0.001), hippocampus (p < 0.001), and amygdala (p < 0.001) were more reduced in patients with PD-MCI or PDD than in patients with PD-NC, and the SUVR of the caudate correlated with caudate volume (r = 0.187, p = 0.015). Hippocampal atrophy was the initial change influencing cognitive impairment. The reduced dopamine availability of the thalamus preceded reductions in volume across most deep gray matter regions. Discussion: Our finding underscores the association between decreased dopamine availability and volume of the caudate and thalamus with cognitive dysfunction in PD. The dopamine availability of the caudate and thalamus was reduced before the volume of the caudate and thalamus was decreased, highlighting the spatiotemporal association between dopaminergic and structural pathology in cognitive impairment in PD.

Cognitive Impairments in Early Parkinson's Disease Are Accompanied by Reductions in Activity in Frontostriatal Neural Circuitry.

Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease

Fronto-striatal Cognitive Deficits at Different Stages of Parkinson's Disease.

Lateralisation of Striatal Function: Evidence from 18F-Dopa PET in Parkinson's Disease.

Brain networks and cognitive impairment in Parkinson’s disease

Altered Cerebellar Resting-State Functional Connectivity in Early-Stage Parkinson's Disease Patients With Cognitive Impairment

Cognitive Impairment in Parkinson's Disease: the Dual Syndrome Hypothesis.

Using Executive Heterogeneity to Explore the Nature of Working Memory Deficits in Parkinson'S Disease

Cognitive Deficits in Parkinson's Disease: A Cognitive Neuroscience Perspective

Neuropsychological and Clinical Heterogeneity of Cognitive Impairment and Dementia in Patients with Parkinson's Disease

Dopaminergic Basis for Deficits in Working Memory but Not Attentional Set-Shifting in Parkinson's Disease

Approach to Cognitive Impairment in Parkinson’s Disease

Cognitive impairment in Parkinson's disease and other parkinsonian syndromes

Impairment of Neuronal Activity in the Dorsolateral Prefrontal Cortex Occurs Early in Parkinsonism

Parkinson disease-associated cognitive impairment

Cognitive performance in mid-stage Parkinson’s disease: functional connectivity under chronic antiparkinson treatment

Conscious attention defect and inhibitory control deficit in Parkinson's Disease-Mild Cognitive Impairment: A comparison study with Amnestic Mild Cognitive Impairment multiple domain

Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition

Altered Prefrontal Blood Flow Related with Mild Cognitive Impairment in Parkinson's Disease: A Longitudinal Study